Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
02 04 2019
02 04 2019
Historique:
received:
09
06
2018
accepted:
06
12
2018
pubmed:
10
3
2019
medline:
18
12
2019
entrez:
10
3
2019
Statut:
ppublish
Résumé
To revise the 1999 Airlie House consensus guidelines for the design and implementation of preclinical therapeutic studies and clinical trials in amyotrophic lateral sclerosis (ALS). A consensus committee comprising 140 key members of the international ALS community (ALS researchers, clinicians, patient representatives, research funding representatives, industry, and regulatory agencies) addressed 9 areas of need within ALS research: (1) preclinical studies; (2) biological and phenotypic heterogeneity; (3) outcome measures; (4) disease-modifying and symptomatic interventions; (5) recruitment and retention; (6) biomarkers; (7) clinical trial phases; (8) beyond traditional trial designs; and (9) statistical considerations. Assigned to 1 of 8 sections, committee members generated a draft set of guidelines based on a "background" of developing a (pre)clinical question and a "rationale" outlining the evidence and expert opinion. Following a 2-day, face-to-face workshop at the Airlie House Conference Center, a modified Delphi process was used to develop draft consensus research guidelines, which were subsequently reviewed and modified based on comments from the public. Statistical experts drafted a separate document of statistical considerations (section 9). In this report, we summarize 112 guidelines and their associated backgrounds and rationales. The full list of guidelines, the statistical considerations, and a glossary of terms can be found in data available from Dryad (appendices e-3-e-5, doi.org/10.5061/dryad.32q9q5d). The authors prioritized 15 guidelines with the greatest potential to improve ALS clinical research. The revised Airlie House ALS Clinical Trials Consensus Guidelines should serve to improve clinical trial design and accelerate the development of effective treatments for patients with ALS.
Identifiants
pubmed: 30850440
pii: WNL.0000000000007242
doi: 10.1212/WNL.0000000000007242
pmc: PMC6448453
doi:
Substances chimiques
Biomarkers
0
Types de publication
Consensus Development Conference
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1610-e1623Subventions
Organisme : Motor Neurone Disease Association
ID : TURNER/OCT18/989-797
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : U13 NS093847
Pays : United States
Informations de copyright
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Lancet Neurol. 2016 Oct;15(11):1182-94
pubmed: 27647646
Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:5-18
pubmed: 23678876
Neurotherapeutics. 2015 Apr;12(2):394-402
pubmed: 25502407
Oxid Med Cell Longev. 2016;2016:9345970
pubmed: 26798428
J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):38-44
pubmed: 24336810
Lancet Neurol. 2017 Dec;16(12):976-986
pubmed: 29066163
Ann Neurol. 2014 Nov;76(5):643-57
pubmed: 25223628
J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1180-5
pubmed: 25886781
Contemp Clin Trials. 2012 Jan;33(1):218-22
pubmed: 21996525
Mamm Genome. 2011 Aug;22(7-8):420-48
pubmed: 21706386
Nat Rev Neurol. 2015 Jun;11(6):360-6
pubmed: 25939274
Lancet Neurol. 2018 May;17(5):423-433
pubmed: 29598923
Nat Biotechnol. 2011 May;29(5):411-4
pubmed: 21516084
Sci Transl Med. 2016 Jul 13;8(347):347ra93
pubmed: 27412785
Neurology. 2016 Mar 1;86(9):813-20
pubmed: 26802094
Patient. 2013;6(3):179-87
pubmed: 23736943
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):574-81
pubmed: 23952636
Exp Neurol. 2013 Oct;248:1-9
pubmed: 23707216
Lancet Neurol. 2014 Nov;13(11):1127-1138
pubmed: 25316019
Nat Rev Neurol. 2011 Sep 27;7(11):650-4
pubmed: 21947135
J Neurol Sci. 1999 Oct 31;169(1-2):2-12
pubmed: 10540001
Trends Pharmacol Sci. 2006 May;27(5):267-73
pubmed: 16690390
J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1165-70
pubmed: 21622937
Neuroepidemiology. 1989;8(3):142-50
pubmed: 2725806
Neurology. 2005 Jan 11;64(1):38-43
pubmed: 15642901
Amyotroph Lateral Scler. 2010 May 3;11(3):259-65
pubmed: 19961263
Lancet. 2017 Nov 4;390(10107):2084-2098
pubmed: 28552366
Cell Cycle. 2015;14(23):3679-88
pubmed: 26505672
Nature. 2014 Mar 27;507(7493):423-5
pubmed: 24678540
Neurology. 2004 Nov 23;63(10):1933-5
pubmed: 15557515
Amyotroph Lateral Scler. 2010 Dec;11(6):542-8
pubmed: 20500116
J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):45-9
pubmed: 24463480
Muscle Nerve. 2014 Mar;49(3):441-3
pubmed: 24273034
J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):30-2
pubmed: 17634215
Amyotroph Lateral Scler. 2010;11(1-2):116-21
pubmed: 19551536
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):1-8
pubmed: 24588460
Curr Protoc Pharmacol. 2015 Jun 01;69:5.67.1-5.67.21
pubmed: 26344214
Lancet Neurol. 2013 Nov;12(11):1059-67
pubmed: 24067398
Neurology. 2009 Feb 24;72(8):725-31
pubmed: 19237701
Amyotroph Lateral Scler. 2009 Jun;10(3):131-46
pubmed: 19462523
Science. 2014 Jul 18;345(6194):1247125
pubmed: 25035496
Lancet Neurol. 2006 Feb;5(2):140-7
pubmed: 16426990
Neurotherapeutics. 2017 Jul;14(3):762-772
pubmed: 28070747
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Apr;14(3):162-8
pubmed: 23323713
Amyotroph Lateral Scler. 2008;9(1):16-23
pubmed: 18273715
Lancet Neurol. 2017 Jul;16(7):505-512
pubmed: 28522181
Muscle Nerve. 2004 Nov;30(5):676-8
pubmed: 15452839
Hum Genet. 2012 Apr;131(4):535-63
pubmed: 22167414